Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

380 ARTÍCULOS , VIENDO DEL 166 AL 180

Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease

Yildirim Simsir I, Soyaltin UE, Cetinkalp S.

Diabetes Metab Syndr. 2018 May;12(3):469-475. doi: 10.1016/j.dsx.2018.03.002. Epub 2018 Mar 16.

Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?

Cacabelos R.

Expert Opin Drug Discov. 2018 Jun;13(6):523-538. doi: 10.1080/17460441.2018.1457645. Epub 2018 Apr 1.

Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study

Reed C, Belger M, Dell'Agnello G, Kahle-Wrobleski K, Sethuraman G, Hake A, Raskin J, Henley D.

Alzheimers Res Ther. 2018 Apr 3;10(1):36. doi: 10.1186/s13195-018-0360-4.

A Literature Review of Methodologies Used in Randomized Clinical Trials of Agitation in Alzheimer's Disease

Dubé S, Megerian JT, Malamut R.

J Prev Alzheimers Dis. 2018;5(2):120-133. doi: 10.14283/jpad.2018.17.

The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial

Wessels AM, Andersen SW, Dowsett SA, Siemers ER.

J Prev Alzheimers Dis. 2018;5(2):134-136. doi: 10.14283/jpad.2018.10.

Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease

Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L.

J Prev Alzheimers Dis. 2018;5(2):149-154. doi: 10.14283/jpad.2018.18.

A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

Fullerton T, Binneman B, David W, Delnomdedieu M, Kupiec J, Lockwood P, Mancuso J, Miceli J, Bell J.

Alzheimers Res Ther. 2018 Apr 5;10(1):38. doi: 10.1186/s13195-018-0368-9.

New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease

Zhong KL, Chen F, Hong H, Ke X, Lv YG, Tang SS, Zhu YB.

Metab Brain Dis. 2018 Aug;33(4):1009-1018. doi: 10.1007/s11011-018-0227-1. Epub 2018 Apr 6.

Informed consent to research trials on Alzheimer's disease: How to foster research without infringing upon the patient's right to self-determination

Montanari Vergallo G, Cisale GY, di Luca NM, Marinelli E, Zaami S.

Pharmacol Res. 2018 Jun;132:69-71. doi: 10.1016/j.phrs.2018.04.001. Epub 2018 Apr 4.

Anti-Aβ drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease

Lee D , Lee G , Yoon DS .

Analyst. 2018 May 15;143(10):2204-2212. doi: 10.1039/c7an02013a.

The GABAergic system as a therapeutic target for Alzheimer's disease

Calvo-Flores Guzmán B, Vinnakota C, Govindpani K, Waldvogel HJ, Faull RLM, Kwakowsky A.

J Neurochem. 2018 Sep;146(6):649-669. doi: 10.1111/jnc.14345. Epub 2018 Aug 1.

Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework

Khachaturian AS, Hayden KM, Mielke MM, Tang Y, Lutz MW, Gustafson DR, Kukull WA, Mohs R, Khachaturian ZS.

Alzheimers Dement. 2018 Apr;14(4):532-534. doi: 10.1016/j.jalz.2018.03.003.

The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable

Knopman DS, Haeberlein SB, Carrillo MC, Hendrix JA, Kerchner G, Margolin R, Maruff P, Miller DS, Tong G, Tome MB, Murray ME, Nelson PT, Sano M, Mattsson N, Sultzer DL, Montine TJ, Jack CR Jr, Kolb H, Petersen RC, Vemuri P, Canniere MZ, Schneider JA, Resnick SM, Romano G, van Harten AC, Wolk DA, Bain LJ, Siemers E.

Alzheimers Dement. 2018 Apr;14(4):563-575. doi: 10.1016/j.jalz.2018.03.002.

Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy

Verma S, Kumar A, Tripathi T, Kumar A.

J Pharm Pharmacol. 2018 Aug;70(8):985-993. doi: 10.1111/jphp.12919. Epub 2018 Apr 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias